Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$63.22 USD

63.22
151,890

-0.28 (-0.44%)

Updated Jul 15, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Momentum in ANI (ANIP) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, ANI (ANIP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Eton Pharmaceuticals, Inc. (ETON) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ANI (ANIP) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ANI Pharmaceuticals (ANIP) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 100% and 20.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -248.78% and 88.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed the most recent trading day at $52.79, moving +1.15% from the previous trading session.

ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed the most recent trading day at $51.89, moving +1.07% from the previous trading session.

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and ImmunoGen (IMGN) have performed compared to their sector so far this year.

ANI Pharmaceuticals (ANIP) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $51.30, marking a +0.33% move from the previous day.

Ensign Group (ENSG) Up 26% in a Year: More Room to Run?

by Zacks Equity Research

Ensign Group (ENSG) is well-poised for growth on the back of an aging U.S. population, an expanding healthcare portfolio and prudent deployment of capital.

GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag

by Zacks Equity Research

The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.

Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy

by Zacks Equity Research

Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.

Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs

by Zacks Equity Research

Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.

DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly

by Zacks Equity Research

DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.

ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business

by Zacks Equity Research

AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China.

2seventy (TSVT) Down 9% on Patient Death in Leukemia Study

by Zacks Equity Research

Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is still unclear whether the death was due to the treatment.

Humana (HUM) Wins Contract to Serve Oklahoma's Medicaid Members

by Zacks Equity Research

Humana (HUM) secures a contract from the OHCA and is likely to provide improved health outcomes for Medicaid members of Oklahoma.

Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

by Zacks Equity Research

A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.

Tenet Healthcare (THC) Gains 42.1% YTD: More Room to Run?

by Zacks Equity Research

Tenet Healthcare's (THC) aim to boost USPI's network through continuous buyouts is positioning the company well for growth.